Arie Lazarovich, President
For over two decades, the pharmaceutical, biotechnology, and medical device industries have undergone drastic changes with regards to technologies, regulations, and processes. In this ever-changing landscape, Clinical Trials Group (CTG) has been constantly offering exceptional quality services to its global clientele base, efficiently adapting to these changes, and always dedicated to providing quality services and serving the interests of its clients. With the CRO industry playing an increasingly more significant role in the global pharmaceutical industry R&D activities—as more and more research activities are outsourced towards the CRO industry—CTG stands at the forefront as a high-quality ISO-certified full-service provider of drug development-related services.
To put things in perspective, many firms face currently pressing timelines in conducting successful clinical research, owing to the over permeation of multiple trials, difficulties in recruitment, low patient retention rates, and higher costs associated with such trials. These challenges are expected to further increase in the future.
Amidst such growing disparities, central and south-eastern Europe gradually emerged as a “golden buzzer” for global sponsors as it offers ample patient participation, low drop off rates and qualitative trial data, combined with significantly lower costs and study approval and execution timelines. Consequently, over the years, the percentage of global studies conducted in C&SEE has increased constantly. “Central and south-east European countries are not saturated and present us with faster and higher recruitment, lower drop-off rates, quality data, and reduced study costs. Furthermore, the region is “heaven” for a number of therapeutic areas, based on the multigenetic characteristics of its population,” states CTG’s President, Arie Lazarovich.
CTG is a pioneer in this growing but also heterogeneous and multicultural territory. With over 20 years of experience in both global and local CRO landscape, the company extends today a complete range of project management and consultancy services to the pharmaceutical, biotechnology, and medical device industries. “CTG combines the advantages of a regional CRO with the extensive experience, know-how, and understanding acquired through a history of successfully managing global clinical trials in the highest quality standards around the world,” says Lazarovich.
CTG has a rich experience across all study phases (I-IV) in diverse therapeutic areas such as cardiology, oncology, CNS, immunology, respiratory, digestive, neurology, and many more.
CTG combines the advantages of a regional CRO with the extensive experience, know-how and understanding acquired through a history of successfully managing global clinical trials in the highest quality standards around the world
From study design, accurate feasibility across the region, protocol writing, and adaptation in resonance with the country regulations, all the way to study conduct and management, CTG serves as a trusted medical research partner to its clients throughout the entire study cycle.
Added to this, the company assists clients with strategic advice on biostatistical services, management visibility, first touch in the market, and vendor and site management, and often acts as the legal representative for its clients in Europe.
Piggybacking on its quality personalised services, CTG extends its services based on scientific criteria, as well as in accordance with respective legal frameworks, national and international guidelines, ICH, GCP, and SOPs. “Our uniqueness emanates from our understanding of the local regulations, and our extensive connections with all local stakeholders—regulatory authorities, local centres, doctors, hospitals, opinion leaders—across central and south-eastern Europe, as well as our reputation and long-time relations. All these elements were gained over a long period of commitment and years, allow us to deploy successful and qualitative clinical trials, and even manage FDA filings for account of our clients,” continues Lazarovich. CTG’s value proposition in the market also stems from the flexibility it delivers in carrying out clinical research across the globe according to the client requirements and its unique ability to seamlessly integrate into their SOPs, culture, and systems. The company’s professional and medically experienced staff offers robust and highly personalised services, regardless of their location.
Apart from its two-decade-long industry experience, CTG also attributes its success to its “quality” culture that is inherent throughout the entire clinical trial management process. “We have an excellent track record of successful audits from regulatory authorities, including FDA, as well as multiple global sponsors, which serves as a proof of the quality standards we operate with and deliver to our clients,” he adds.
Having secured a solid brand name across Europe with offices and presence in many countries in C&SEE region, CTG is actively promoting strategic partnerships in other key geographical regions (such as North America, MENA, Asia, etc.), in order to further increase its offering to the global pharma and medical device industry. At the same time, it will also be continuously investing in internal IT systems, including electronic CRS and data management, to augment the clinical research and regulatory audit services the company provides to its clients.